Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 445

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Fibroblast Growth Factor-23 and Cardiovascular Events in CKD

Open access
Scialla, Julia J., Xie, Huiliang, Rahman, Mahboob, Anderson, Amanda Hyre, Isakova, Tamara, Ojo, Akinlolu, Zhang, Xiaoming, Nessel, Lisa, Hamano, Takayuki, Grunwald, Juan E., Raj, Dominic S., Yang, Wei, He, Jiang, Lash, James P., Go, Alan S., Kusek, John W., Feldman, Harold, Wolf, Myles·2014·Journal of the American Society of Nephrology

Abstract

An elevated level of fibroblast growth factor-23 (FGF-23) is the earliest abnormality of mineral metabolism in CKD. High FGF-23 levels promote left ventricular hypertrophy but not coronary artery calcification. We used survival analysis to determine whether elevated FGF-23 is associated with greater risk of adjudicated congestive heart failure (CHF) and atherosclerotic events (myocardial infarction, stroke, and peripheral vascular disease) in a prospective cohort of 3860 participants with CKD stages 2-4 (baseline estimated GFR [eGFR], 44±15 ml/min per 1.73 m(2)). During a median follow-up of 3.7 years, 360 participants were hospitalized for CHF (27 events/1000 person-years) and 287 had an atherosclerotic event (22 events/1000 person-years). After adjustment for demographic characteristics, kidney function, traditional cardiovascular risk factors, and medications, higher FGF-23 was independently associated with graded risk of CHF (hazard ratio [HR], 1.45 per doubling [95% confidence interval (CI), 1.28 to 1.65]; HR for highest versus lowest quartile, 2.98 [95% CI, 1.97 to 4.52]) and atherosclerotic events (HR per doubling, 1.24 [95% CI, 1.09 to 1.40]; HR for highest versus lowest quartile, 1.76 [95% CI, 1.20 to 2.59]). Elevated FGF-23 was associated more strongly with CHF than with atherosclerotic events (P=0.02), and uniformly was associated with greater risk of CHF events across subgroups stratified by eGFR, proteinuria, prior heart disease, diabetes, BP control, anemia, sodium intake, income, fat-free mass, left ventricular mass index, and ejection fraction. Thus, higher FGF-23 is independently associated with greater risk of cardiovascular events, particularly CHF, in patients with CKD stages 2-4.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2013050465

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 445

Metadata

Authors
Scialla, J. J., Xie, H., Rahman, M., Anderson, A. H., Isakova, T., Ojo, A., Zhang, X., Nessel, L., Hamano, T., Grunwald, J. E., Raj, D. S., Yang, W., He, J., Lash, J. P., Go, A. S., Kusek, J. W., Feldman, H., & Wolf, M.
Venue
Journal of the American Society of Nephrology
Published
2014-02
Volume
25
Issue
2
Pages
349-360
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2100168006
Cited by
445
References
47
FWCI
24.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. https://app.cochat.ai/papers/10.1681/asn.2013050465
The paper
Scialla, J. J., Xie, H., Rahman, M., Anderson, A. H., Isakova, T., Ojo, A., Zhang, X., Nessel, L., Hamano, T., Grunwald, J. E., Raj, D. S., Yang, W., He, J., Lash, J. P., Go, A. S., Kusek, J. W., Feldman, H., & Wolf, M. (2014). Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2013050465

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.